Transjugular Intrahepatic Portosystemic Shunt (TIPS): early laboratory changes and correlations with short-term mortality
Author Block: F. Schön, T. Helmberger, M. Berning, S. F. U. Blum, C. Radosa, S. Löck, R-T. Hoffmann, J-P. Kühn; Dresden/DE
Purpose: To investigate early laboratory changes following Transjugular Intrahepatic Portosystemic Shunt (TIPS) and their associations with short-term mortality.
Methods or Background: TIPS procedures from 2017 to 2023 were enrolled retrospectively. Laboratory parameters (INR, ALAT, ASAT, GGT and bilirubin) were assessed once pre-procedurally, on post-procedural days 1 or 2, and once again between days 5 and 7. Percentage changes from baseline were calculated for each parameter. Temporal changes of the parameters were assessed using Kruskal-Wallis tests, and comparisons regarding 30-day mortality were evaluated using Mann-Whitney U tests.
Results or Findings: A total of 245 TIPS procedures (161 men, mean age 59.8 +/- 10.9 years) were enrolled, with a technical success rate of 95.5% (234/245). All laboratory parameters significantly increased post-procedurally (p < 0.001). ALAT and ASAT revealed the highest increase within the first two post-procedural days (+374 +/- 1118%, and +450 +/- 1079%, respectively), followed by decreases on days 5-7 (+279 +/- 568%, and +125 +/- 233%, respectively). Patients who died within 30 days (n = 17) had significantly higher baseline INR (p = 0.009), ASAT (p = 0.014) and bilirubin (p = 0.011), while GGT was lower (p = 0.012). 30-day mortality was associated with a higher increase of ASAT and GGT on days 1/2 (+1361 +/- 2202% vs. +415 +/- 954%, p = 0.029; and +56 +/- 101% vs. +21 +/- 51%, p = 0.034, respectively).
Conclusion: TIPS significantly impacts liver function, with marked early increases of ALAT and ASAT levels. Pronounced increase of laboratory parameters within the first two post-procedural days might help to identify high-risk patients in terms of short-term mortality.
Limitations: Retrospective study design with a relatively small number of patients.
Funding for this study: Not applicable.
Has your study been approved by an ethics committee? Yes
Ethics committee - additional information: The present study was approved by the local ethics committee (BO-EK-501122023).